HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.
SHANGHAI & JERSEY CITY, N.J. Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License ...
A father and son both died in their sleep after going to bed with runny noses and tickly throats. Jason Selvey died aged 47 ...
Accord BioPharma Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that Express Scripts, one of ...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with ...
PregaTips on MSN
Symptoms, risks, diagnosis, and treatment
Congenital Diaphragmatic Hernia (CDH) is a rare birth condition where a baby’s diaphragm does not form fully, causing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback